Abstract
Background Prostate-specific membrane antigen- (PSMA-) targeted agents labeled with fluorine-18 (18F) have recently become available to evaluate patients with biochemical recurrent prostate cancer (BRPCa) by using positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI). We performed a systematic review and meta-analysis about the detection rate (DR) of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa patients. Methods A comprehensive computer literature search of PubMed/MEDLINE, EMBASE, and Cochrane Library databases for studies published through 17 May 2021 was carried out using the following search algorithm: “PSMA” AND “1007”. Only studies providing data on the DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa were included. A random-effects model was used to calculate the pooled DR on a per scan basis. Results Fifteen articles (853 patients) were selected and included in the systematic review, and ten were included in the quantitative analysis. Most of the studies reported a good DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa including also patients with low prostate-specific membrane antigen (PSA) values. The DR of 18F-PSMA-1007 PET/CT or PET/MRI was dependent on PSA serum values. The pooled DR was 81.3% (95% confidence interval: 74.6–88%) with statistical heterogeneity. A significant reporting bias (publication bias) was not detected. Conclusions 18F-PSMA-1007 PET/CT or PET/MRI showed a good DR in BRPCa patients in line with other PSMA-targeted agents. The DR of 18F-PSMA-1007 PET/CT or PET/MRI is influenced by serum PSA values. These findings should be confirmed by prospective multicentric trials.
Highlights
Between 27% and 53% of all patients with prostate cancer (PCa) undergoing radical prostatectomy (RP) or radiation therapy (RT) develop a biochemical recurrence (BCR) defined as rising prostate-specific antigen (PSA) serum levels after curative treatment for PCa [1]
18F-prostate-specific membrane antigen- (PSMA-)1007 PET/ CT or PET/magnetic resonance imaging (MRI) showed a good detection rate (DR) in biochemical recurrent prostate cancer (BRPCa) patients in line with other PSMA-targeted agents. e DR of 18F-PSMA-1007 PET/ CT or positron emission tomography/magnetic resonance imaging (PET/MRI) is influenced by serum PSA values. ese findings should be confirmed by prospective multicentric trials
Our report is the first systematic review and meta-analysis focused on 18F-PSMA-1007 positron emission tomography/computed tomography (PET/CT) or PET/ MRI in BRPCa patients
Summary
Between 27% and 53% of all patients with prostate cancer (PCa) undergoing radical prostatectomy (RP) or radiation therapy (RT) develop a biochemical recurrence (BCR) defined as rising prostate-specific antigen (PSA) serum levels after curative treatment for PCa [1]. Using prostate-specific membrane antigen- (PSMA-) targeted agents have been recognized as useful techniques in improving the diagnosis of biochemical recurrent prostate cancer (BRPCa) [2,3,4,5]. Prostate-specific membrane antigen- (PSMA-) targeted agents labeled with fluorine-18 (18F) have recently become available to evaluate patients with biochemical recurrent prostate cancer (BRPCa) by using positron emission tomography/ computed tomography (PET/CT) or positron emission tomography/magnetic resonance imaging (PET/MRI). We performed a systematic review and meta-analysis about the detection rate (DR) of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa patients. Most of the studies reported a good DR of 18F-PSMA-1007 PET/CT or PET/MRI in BRPCa including patients with low prostate-specific membrane antigen (PSA) values. 18F-PSMA-1007 PET/ CT or PET/MRI showed a good DR in BRPCa patients in line with other PSMA-targeted agents. Conclusions. 18F-PSMA-1007 PET/ CT or PET/MRI showed a good DR in BRPCa patients in line with other PSMA-targeted agents. e DR of 18F-PSMA-1007 PET/ CT or PET/MRI is influenced by serum PSA values. ese findings should be confirmed by prospective multicentric trials
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
